Progress in Respiratory Virus Vaccine Development
- 19 August 2011
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 32 (04) , 527-540
Abstract
Viral respiratory infections cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing respiratory disease, vaccine development has to focus on a limited number of pathogens, such as those that commonly cause serious lower respiratory illness (LRI). Whereas influenza virus vaccines have been available for some time (see the review by Clark and Lynch in this issue), vaccines against other medically important viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIVs), and metapneumovirus (MPVs) are not available. This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development.Keywords
This publication has 96 references indexed in Scilit:
- Viral Etiology of Severe Pneumonia Among Kenyan Infants and ChildrenJAMA, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunizationVaccine, 2010
- Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeysVaccine, 2010
- The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutationsMolecular Immunology, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Development and preclinical evaluation of an alphavirus replicon vaccine for influenzaVaccine, 2007
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesVaccine, 2007
- Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primatesVaccine, 2007
- Alphavirus replicon approach to promoterless analysis of IRES elementsVirology, 2007